FDA warns stem cell company over unapproved treatments

04-06-2019

FDA warns stem cell company over unapproved treatments

Giovanni Cancemi / Shutterstock.com

The US Food and Drug Administration (FDA) has sent a warning letter to a stem cell company for marketing a number of unapproved treatments for a variety of life-threatening conditions.


US Food and Drug Administration, R3 Stem Cell, stem cell, diabetes, Lyme disease, Public Health Service Act

LSIPR